Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Abstract

IntroductionPlasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins.Methods4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid.ResultsA panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization.DiscussionThe results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.

Novel Blood-Derived Extracellular Vesicle-Based Biomarkers in Alzheimer’s Disease Identified by Proximity Extension Assay

“…Discovery-based studies require large-scale measurements of multiple proteins based on methods like mass spectrometry, immunological methods, or combinations thereof. A variety of the mentioned methods have previously been used in studies of AD for investigating markers of disease in both plasma [ 23 , 24 ] and EVs [ 13 , 16 , 25 , 26 ] although often with conflicting results. Mass spectrometry is biased towards abundant proteins, making detection of low abundant proteins a challenge [ 27 ].…”

Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis

“…Finally, few studies have carried out an external clinical validation of potential biomarkers (plasma proteins, magnetic resonance imaging scans) differentiating two groups of participants (discovery group, validation group) [59,60]. In order to improve the statistical power, other studies developed an internal clinical validation [61,62].…”

Aging Biomarkers: From Functional Tests to Multi‐Omics Approaches

“…Thus, SOMAscan assay, a Slow Off‐rate Modified Aptamer (SOMAmer)‐based capture array, covers now more than 4000 unique plasma proteins, whose concentrations vary by eight orders of magnitude. [ 125 ] This and similar high‐throughput multiplexing platforms have already been applied to exam age‐associated alterations at the human sub‐proteomes.…”